Table 2.
Comparison of demographic and clinical characteristics between Parkinson disease patients that remained without OH during the follow-up period (OH–) and patients without OH at baseline that developed OH during the follow-up period; and asymptomatic and symptomatic OH patients within the OH+ group based on initial visit with OH.
| OH– patients (n = 14) | OH+ patients (n = 28) | p-value for OH– vs. OH+ | aOH patients (n = 13) | sOH patients (n = 13) | p-value for aOH vs. sOH | |
|---|---|---|---|---|---|---|
| Baseline age, years | 58.3 (11.0) | 62.7 (11.0) | 0.22 | 64.1 (14.0) | 63.2 (7.4) | 0.72 |
| Sex, female (%) | 4 (28.6) | 9 (32.1) | 1.00 | 5 (38.5) | 4 (30.8) | 1.00 |
| Education, years | 15.1 (3.3) | 15.8 (3.2) | 0.41 | 16.0 (2.4) | 15.2 (3.7) | 0.73 |
| Baseline disease duration, years | 2.4 (1.9) | 3.2 (2.4) | 0.39 | 3.1 (1.8) | 4.5 (2.7) | 0.20 |
| Follow-up interval, years | 5.0 (1.1) | 5.5 (1.3) | 0.26 | 5.7 (1.0) | 5.3 (1.5) | 0.28 |
| Baseline Hoehn & Yahr scale | 1.6 (0.6) | 1.8 (0.5) | 0.45 | 1.8 (0.6) | 2.0 (0.4) | 0.40 |
| Follow-up Hoehn & Yahr scale | 2.1 (0.7) | 2.3 (0.6) | 0.55 | 2.2 (0.6) | 2.4 (0.7) | 0.43 |
| Baseline MDS-UPDRS Part 3 | 21.1 (15.4) | 21.0 (9.4) | 0.61 | 23.2 (10.5) | 22.6 (8.6) | 0.82 |
| Follow-up MDS-UPDRS Part 3 | 25.1 (15.5) | 21.8 (12.7) | 0.59 | 19.9 (11.1) | 22.5 (12.6) | 0.49 |
| Baseline MoCA | 25.8 (3.1) | 26.1 (2.4) | 0.97 | 25.8 (2.1) | 25.1 (2.6) | 0.66 |
| Follow-up MoCA | 25.6 (4.1) | 25.0 (4.7) | 0.74 | 26.9 (3.0) | 25.1 (3.9) | 0.22 |
All variables are reported as mean (standard deviation) or percentage. Follow-up visits indicate last visits during follow-up interval. The results reported in this table are the results of Fisher's exact test and Mann–Whitney U-test.
OH, orthostatic hypotension; OH–, without OH; OH+, with OH; aOH, asymptomatic OH; sOH, symptomatic OH; MDS-UPDRS, Movement Disorders Society Unified Parkinson Disease Rating Scale; MoCA, Montreal Cognitive Assessment.